Related Experiment Videos
[Immunosuppressive treatment strategy in connective tissue diseases]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 17, 1999
Summary
This review covers immunosuppressive agents for connective tissue diseases, highlighting cyclophosphamide for lupus nephritis and Wegener's granulomatosis. It also discusses newer agents and managing side effects for improved treatment strategies.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Context:
- Connective tissue diseases (CTDs) often require management with immunosuppressive agents.
- Advances in immunosuppressive therapy have significantly impacted CTD treatment over the past decade.
- Steroid-refractory organ involvement presents a therapeutic challenge in CTDs.
Purpose:
- To review key literature on immunosuppressive agents in CTDs.
- To highlight significant therapeutic advancements, including cyclophosphamide therapies.
- To discuss the role of newer agents and adverse effect management.
Summary:
- Cyclophosphamide (intravenous for lupus nephritis, oral for Wegener's granulomatosis) represents a major progress in CTD treatment.
- Newer agents like cyclosporine and tacrolimus are valuable for steroid-refractory organ involvements.
- Effective monitoring and prevention of adverse effects are crucial for optimizing immunosuppressive therapy.
Impact:
- Provides an overview of current immunosuppressive treatment strategies for CTDs.
- Informs clinicians about established and emerging therapeutic options.
- Emphasizes the importance of managing treatment-related toxicities for patient outcomes.